Form 4: Anixa Biosciences Director Acquires 10,000 Shares

Anixa Biosciences director Lewis H. Titterton Jr. purchased 10,000 shares of common stock at $2.57 per share on January 17, 2025.

Summary

• On January 17, 2025, Lewis H. Titterton Jr., a director at Anixa Biosciences, acquired 10,000 shares of the company's common stock.
• The shares were purchased at a price of $2.57 per share.
• Following this transaction, Mr. Titterton directly owns 922,334 shares of Anixa Biosciences common stock.

Sentiment

Score: 6

Explanation: The document is a routine disclosure of a director's stock purchase. It is neither overwhelmingly positive nor negative, but the purchase could be interpreted as a sign of confidence.

Positives

• The director's purchase of shares could be seen as a positive sign of confidence in the company's future prospects.

Industry Context

This is a standard SEC Form 4 filing, which is common for corporate insiders who trade their company's stock. It provides transparency into the trading activities of company directors.

Comparison to Industry Standards

• SEC Form 4 filings are a standard practice for publicly traded companies in the United States.
• The transaction is typical for directors who may buy or sell shares of their company.
• The size of the transaction is not unusual for a director's personal investment.

Stakeholder Impact

• The stock purchase may have a minor positive impact on shareholder sentiment.

Key Dates

Keywords

Anixa Biosciences, insider trading, stock purchase, director, share acquisition, common stock, Lewis H. Titterton Jr.